Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

详细信息	查看全文 | 推荐本文 |

• 作者：Javier Carbajo-Lozoya^a ; Marcel A. Mü ; ller^b ; Stephan Kallies^b ; Volker Thiel^c ; ^d ; Christian Drosten^b ; Albrecht von Brunn^a ; ^{vonbrunn@mvp.uni-muenchen.de}
• 关键词：EC50 ; 50%effective inhibitory concentration ; RLU ; relative light units
• 刊名：Virus Research
• 出版年：2012
• 期刊代码：92_01681702
• 类别：imm
• 出版时间：April, 2012
• 卷：165
• 期：1
• 页码：112-117
• 文件大小：920 K

摘要

Recent research has shown that Coronavirus (CoV) replication depends on active immunophilin pathways. Here we demonstrate that the drug FK506 (Tacrolimus) inhibited strongly the growth of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E at low, non-cytotoxic concentrations in cell culture. As shown by plaque titration, qPCR, Luciferase- and green fluorescent protein (GFP) reporter gene expression, replication was diminished by several orders of magnitude. Knockdown of the cellular FK506-binding proteins FKBP1A and FKBP1B in CaCo2 cells prevented replication of HCoV-NL63, suggesting the requirement of these members of the immunophilin family for virus growth.